The 2024 Pharm Exec 50 list released by Pharm Exec magazine in the United States, and Johnson & Johnson, AbbVie and Novartis are among the top three. Among the R&D spending, Merck is close to $30 billion at most, and Johnson & Johnson, Roche, Pfizer and AstraZeneca have also spent more than $10 billion on R&D.
Four Chinese pharmaceutical companies have entered the list of the top 50 global pharmaceutical companies. Among them, Yunnan Baiyao ranked 33rd, China Biopharmaceutical ranked 38th, Shanghai Pharmaceutical Group ranked 42nd, and Jiangsu Hengrui Pharmaceutical ranked 48th.
The ranking is based on prescription drug sales data from major pharmaceutical companies in fiscal year 2023. The annual list data of "Pharmaceutical Managers" comes from the global pharmaceutical market research institute Evaluate, which focuses on the prescription drug sales of global pharmaceutical companies, so it has been valued by corporate annual summaries and medical institutions.
Ranking Company Headquarters Annual sales of prescription drugs / Annual R&D investment
1. Johnson & Johnson (Johnson & Johnson) United States $53.463 billion/$14.805 billion
2. AbbVie (AbbVie) United States $52.734 billion/$7.029 billion
3. Novartis Switzerland $52.473 billion/$8.600 billion
4. Merck & Co. (Merck & Co. in North America) U.S. $50.846 billion/$29.711 billion
5. Roche Switzerland $49.110 billion/$14.743 billion
6. Pfizer (Pfizer) United States $48.218 billion/$10.679 billion
7. Bristol-Myers Squibb (Bristol-Myers Squibb) United States $44.398 billion/$9.112 billion
8. AstraZeneca (AstraZeneca) UK $43.790 billion/$10.267 billion
9. Sanofi France $40.805 billion/$7.278 billion
10. GlaxoSmithKline (GSK) UK $36.758 billion/$7.152 billion
11. Novo Nordisk (Novo Nordisk) Denmark $33.722 billion/$4.710 billion
12. Eli Lilly (Eli Lilly) United States $31.868 billion/$9.313 billion
13. Takeda (Takeda) Japan 27.687 billion US dollars/4.776 billion US dollars
14. Amgen (Amgen) United States $26.621 billion/$4.700 billion
15. Gilead Science (Gilead Science) United States $26.461 billion/$5.720 billion
16. Boehringer-Ingelheim (Boehringer-Ingelheim) Germany $20.613 billion/$5.733 billion
17. Bayer Germany $17.663 billion/$5.810 billion
18. Viatris, United States, $15.228 billion/$758 million
19. CSL Australia $14.176 billion/$1.451 billion
20、梯瓦(Teva Pharmaceutical Industries) 以色列 125.00亿美元/9.53亿美元
21. Astellas Pharma Japan $10.377 billion/$1.941 billion
22. Vertex Pharmaceuticals (Vertex Pharmaceuticals) U.S. $9.869 billion/$3.152 billion
23. Sandoz Group, Switzerland, $9.647 billion/$915 million
24. Merck KGaA Germany $8.711 billion/$2.645 billion
25. Daiichi Sankyo Japan $8.091 billion/$2.588 billion
26. Otsuka Holdings Japan $7.970 billion/$2.195 billion
27. Biogen (Biogen) United States $7.247 billion/$2.262 billion
28. Regeneron Pharmaceuticals United States $7.078 billion/$4.408 billion
29. Moderna (Moderna) United States $6.671 billion/$4.845 billion
30. Organon United States $6.142 billion/$516 million
31. Grifols Spain $6.012 billion/$428 million
32、太阳制药(Sun Pharmaceutical Industries) 印度 57.89亿美元/4.47亿美元
33、云南白药(Yunnan Baiyao Group) 中国 55.19亿美元/4700万美元
34. UCB Belgium $5.210 billion/$1.763 billion
35、施维雅(SERVIER LABORATORIES) 法国 51.13亿美元/--
36. Abbott Laboratories United States $5.039 billion/$2.519 billion
37. Fresenius, Germany, $4.538 billion/$715 million
38. Sino Biopharmaceutical, Hong Kong, China, US$4.433 billion/US$671 million
39、博士康(Bausch Health Companies) 加拿大 44.18亿美元/6.02亿美元
40. Eisai (Eisai) Japan $4.305 billion/$1.130 billion
41、三菱化学集团(Mitsubishi Chemical Group) 日本 42.35亿美元/---
42、上海医药集团(Shanghai Pharmaceuticals Holding) 中国 42.26亿美元/---
43, Chugai Pharmaceutical (被罗氏控股) Japan 40.36 亿美元/11.61亿美元
44. STADA Arzneimittel Germany $3.896 billion/---
45. Menarini Italy $3.840 billion/--
46、爵士制药(Jazz Pharmaceuticals) 爱尔兰 37.37亿美元/8.50亿美元
47. Ipsen France $3.555 billion/$667 million
48. Jiangsu Hengrui Medicine China US$3.232 billion/US$1.093 billion
49. Incyte (Incyte) United States $3.165 billion/$1.628 billion
50、瑞迪博士实验室(Dr.Reddy's Laboratories) 印度 30.07亿美元/2.61亿美元